Table 1.
Full description of patient’s characteristics.
| Patient ID | Gender | Age | Comorbidities | Symptoms at Presentation | CRP, mg/L * at the Baseline (Before Starting DAL) | Allergy | Previous Antibiotic Agent | Risk Factors | Localization | Reasons for DAL | Number of Dalbavancin Administration | Associated Oral Treatment | DAL Toxicities | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 72.4 | Hypertension, dyslipidaemia | Back pain, fever, right leg pain | 132 | None | Vancomycin | Previous MRSA infection | L2-L3-L4 | Early discharge | 4 | Cotrimoxazole | None | Clinical cure |
| 2 | M | 66.4 | Hypertension, dyslipidaemia | Back pain | 64 | None | Vancomycin | Previous MRSA infection | D9-D12 | Early discharge | 4 | Cotrimoxazole | None | Clinical cure |
| 3 | F ° | 57.8 | Metastatic cancer, hypothyroidism, hypertension | Back pain | 119 | None | Vancomycin | Previous Surgery | L3-L4 | Early discharge | 5 | Moxifloxacin | None | Clinical cure |
| 4 | F ° | 82.1 | Hypertension | Back pain | 180 | None | Vancomycin | Previous Surgery | L5-S1-S2 | Early discharge on patient’s request | 14 | None | None | Still ongoing/suppressive treatment |
| 5 | M | 87.5 | CKD, Dyslipidaemia, Diabetes | Back pain, fever, right leg pain | 160 | None | Vancomycin | Previous surgery | L4-S1 | Early discharge | 5 | None | None | Clinical cure |
| 6 | F | 46.8 | None | Back pain | 45 | None | Vancomycin | IVDU | L3-L5 | Early discharge | 3 | Moxifloxacin | None | Clinical cure |
| 7 | F | 59.9 | None | Back pain | 97 | None | Vancomyci, daptomycin | Not known | L3-L5 | Early discharge | 4 | Moxifloxacin | None | Clinical cure |
| 8 | M | 67.9 | Cancer, hypertension, dislypidaemia | Back pain | 165 | None | Vancomycin | Previous surgery | L1-L2 | Early discharge | 4 | Moxifloxacin | None | Clinical cure |
| 9 | F | 68 | None | Back pain | 84 | Penicillin and Fluoroquinolones | Vancomycin + rifampin | Previous surgery | L1-L2-L3 | Early discharge | 3 | None | None | Clinical cure |
| 10 | F | 75 | Obesity | Back pain | 20 | None | Vancomycin | Previous surgery | L2-L3-L4 | Early discharge | 3 | None | None | Clinical cure |
| 11 | F | 94.4 | CKD, Hypertension, Dementia | Back pain | 60 | None | Vancomycin | Not known | L4-L5-S1 | Early discharge | 3 | None | None | Clinical cure |
| 12 | F | 83.6 | CKD, Diabetes, Hypertension | Back pain | 25 | None | Vancomycin | Previous MRSA infection | L2-L3 | Early discharge | 3 | None | None | Clinical cure |
| 13 | M | 50.5 | None | Back pain | 35 | None | Vancomycin | Not Known | L1-L2-L3-L4 | Early discharge | 3 | Moxifloxacin | None | Clinical cure |
| 14 | M | 57 | Depression, hypertension | Back pain | 54 | None | Vancomycin | Not Known | L4-L5 | Early discharge | 3 | Moxifloxacin | None | Clinical cure |
| 15 | M | 38.7 | Depression | Back pain, difficult to remain sited | 175 | None | Vancomycin | IVDU | L5-S1-S2 | Early discharge | 4 | None | None | Clinical cure |
Legend to Table 1. F = female, M = male, CKD = chronic kidney disease, DAL = dalbavancin, IVDU = intravenous drug use, MRSA = methicillin-resistant Staphylococcus aureus, D = dorsal, L = lumbar, S = sacral, CRP = C reactive protein, * = mg/L, normal value < 5 mg/L, ° = patients with TDM monitoring available.